QUEBEC CITY, Oct. 10 /CNW Telbec/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS), a growing global biopharmaceutical company focused on endocrine therapy and oncology, announced today that the closing of its previously announced “bought deal” secondary offering of 3,850,000 subordinate voting shares of Atrium Biotechnologies Inc., originally scheduled for October 10, 2006 has been delayed pending the receipt of one consent letter from the former auditors of HVL Parent Incorporated, a company acquired by Atrium Biotechnologies in December 2005, relating to the financial statements of HVL Parent Incorporated for its fiscal year ended September 30, 2005. The closing is now expected to take place within the next week, subject to the rights of the underwriters under the terms of their agreement with Atrium Biotechnologies, AEterna Zentaris and the other selling shareholders.
